# Romiplostim (Nplate)

> Thrombopoietin-receptor peptibody for immune thrombocytopenia.

Source: https://peptides.cafe/peptide/romiplostim
Category: TPO Mimetic · Hematology
Tag: FDA-Approved · Hematology

## Mechanism
Peptibody (Fc-peptide fusion) containing TPO receptor-binding peptide domains that activate c-Mpl on megakaryocytes, stimulating platelet production without competing with endogenous TPO.

## Research areas
- Chronic immune thrombocytopenia (ITP)
- Pediatric ITP
- Hematopoietic syndrome of acute radiation

## Common research protocols
- Weekly SC: Start 1 mcg/kg SC weekly; titrate to platelet count 50–200 × 10⁹/L (max 10 mcg/kg).

## Study summaries
- "Romiplostim in chronic ITP" — Lancet (2008): Sustained platelet responses vs placebo in splenectomized and non-splenectomized adults.

## Considerations
- FDA-approved.
- Reticulin fiber deposition in bone marrow; thrombosis risk with over-correction.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.